F-Prime’s Summer Internship Program: Meet our 2023 interns and fellows

Thank you to our interns and fellow for their contributions this summer and for choosing F-Prime!

This summer, F-Prime was thrilled to welcome a talented cohort of interns and fellows to our Cambridge and London offices to help with competitive landscape analysis, sourcing, founder calls, and more. Read on to learn what it’s like to join our internship program.

“I have been able to explore new thematic areas in which the team was still building its knowledge base. By getting deep into the science and innovation through meeting entrepreneurs and academics, I have added to the team’s thinking and identified potential plays which culminated in presentations to the partners. A special shout out to Ana and Martin for the mentorship and support over the summer!”

 

“My time was split between assisting with an ongoing deal — leading a summer exploration project — and taking part in meetings with potential investments. I’ve had a great time in all of these activities, but I particularly enjoyed being an integral part of a deal team. Between self-guided research into standards of care, calls with key opinion leaders, diving into the relevant primary literature, and doing some basic market forecasting, I was able to leverage the clinical and research training I’ve received and develop so many new skills along the way.”

 

“I have been researching the biotech landscape of foreign markets and performing due diligence on interesting licensing opportunities abroad. I have also participated in many introductory and follow-up meetings with prospective US-based companies, where my research expertise and previous work experience have been invaluable in helping me evaluate each opportunity. I’ve learned a lot throughout the summer and was able to connect with people at all professional levels and across disciplines. One important skill I’ve been able to develop during my time at F-Prime is learning how to become versed in a new area of science within days, which is quite different from my Ph.D. experience of developing deep expertise in one area over many years.”

 

“I joined the F-Prime/FBRI team primarily due to the invaluable opportunity to collaborate with individuals deeply committed to fostering and accelerating my personal learning and professional growth. Although it is a lean team, I am fortunate because it translates to more one-on-one attention. I am getting opportunities to actively participate in diverse projects that make me feel valued as an individual, and that my contributions are noticed and appreciated (even as an intern!).”

 

“I was drawn to F-Prime because of the learning culture at the firm. I wanted to play a role in the translation of good ideas into real medicines and the firm has amazing people doing exactly that. On virtually every topic I encounter, there is a resident expert at the firm who can help me in framing my thinking. This ability to get to the right answer faster makes everyone more productive.

I also want to highlight that the deals the firm sees are a function of its reputation. People want to invest with F-Prime because they know they’ll not only receive capital but also an engaged partner who can help them along the trajectory of the company. This means that we see some of the most interesting ideas that will shape the future of medicine and often get to take part in their realization.”

 

“One of the exhilarating projects I’ve been involved in is the thematic research on Gen AI x Fintech. The possibilities with breakthrough technology like Gen AI are awe-inspiring. I find it fascinating to delve into its potential for the future and hear how visionary entrepreneurs contemplate disrupting the financial services landscape. It’s been an incredible journey so far, and I’m eagerly looking forward to sharing the outcomes of our research.”

 

“I have always planned to spin out my PhD research but had no idea how VCs actually decide to fund these projects. I joined to learn how other spinouts and startups pitch to VCs and learn about the decision processes that VCs make.”

Applications for 2024 are not open yet, but if you are interested in learning more, please send an email to careers@fprimecapital.com.

Why We Invested in Carrot Fertility: A global leader in fertility healthcare and family-forming

Women are half of the world’s population and 80 percent of healthcare consumers, yet efforts to fund women’s health have been marginalized time and time again. In recent years, growing recognition by industry decision-makers has emerged on the varied health challenges faced by women, including increasing demand for fertility services.

While women’s health encompasses vastly more than fertility-related events, the fertility market is much larger than what many people recognize. A recent report from the World Health Organization states around 17.5% of the adult population – one in six people worldwide – experience infertility. The data shows that the market is large and growing. According to the CDC, there were nearly 370,000 assisted reproductive technology (ART) cycles completed in the U.S. in 2021, a 19% increase from 2020.

Enter Carrot Fertility, the leading global fertility care platform enabling employers to offer a highly flexible benefit to support employees in the “pursuit of parenthood” through financial support, care navigation, and provider access.

Tremendous Unmet Need: Traditional healthcare benefits often do not cover family-building.

The fertility and family-building benefits market is accelerating because of favorable demographic and economic trends. Families are having children later in life than they did previously, driving increased interest in solutions for both men and women as they face the prospect of declining fertility. As a result, male and female preservation via freezing of sperm and eggs, respectively, has expanded rapidly.

Further, fertility providers no longer focus exclusively on a narrow demographic, broadening services to be more inclusive of diverse populations. For example, LGBTQ couples are increasingly forming families in ways that benefit from fertility support via surrogacy, assisted reproductive technology, and adoption services.

Tight competition to attract and retain talent at companies is also increasing driving greater attention to these needs, with more family-friendly benefits high on employers’ priority lists. The net result is a more inclusive range of services for everyone who faces fertility-related challenges.

A More Inclusive Solution: Carrot makes family-forming benefits accessible to all.

Many companies focus on spreading their benefits dollars widely, considering women’s health to be a general category alongside mental health, musculoskeletal care, diabetes care, and related “verticals.” The problem with this approach is that it conflates gender with conditions, whereas women’s needs are far more diverse, specific, and complex than can be served with a “women’s health” offering.

Carrot saw an opportunity to develop a compelling solution to a specific problem – fertility – and make it accessible for all, wherever those audiences may be in their fertility and family-forming journey. Fertility care is complicated, and connecting patients with providers and optimal care is just one piece to support them through many of the most meaningful moments of their lives.

“Patients are often left to make care decisions based on limited knowledge, which can lead to unnecessary treatments and poorer care experiences and outcomes. We saw a valuable, important opportunity to provide more women with both connections to care and educational resources to accompany care in order to allow them to make more informed choices.”

-Tammy Sun, CEO, Carrot Fertility

Carrot offers a more inclusive and exhaustive fertility-related benefit that covers all components of and paths to family formation.

  • -Curated Care: Carrot’s substantive network of highly vetted providers enables patients to navigate care options based on their individual needs rather than a predefined, one-size-fits-all course of treatments – all backed by the support of an experienced clinical team.
  • -Cost Savings: Carrot’s financial model enables an employer-specific contribution, rather than a limited benefit for specific surgeries (e.g., IVF), which provides companies with greater flexibility in their benefits offering while adhering to budgets. This allows Carrot to sit alongside patients to advise them about how to make the best use of each employer’s benefits offering.
  • -Global Coverage: By offering benefits on a global basis, Carrot appeals to many buyers of these services who want to offer similar benefits to all employees regardless of their country of residence.
  • -Every Person, Every Journey: Carrot offers evidence-based support for every fertility journey — fertility education, egg and sperm freezing, in vitro fertilization (IVF), pregnancy and postpartum support, gestational surrogacy, adoption, menopause, low testosterone, and more.

Carrot’s platform and wraparound services are already making an impact; quality data released in January 2023 show that Carrot customers had the highest reported single embryo transfer (SET) rate among fertility benefits vendors as well as an IVF pregnancy rate greatly exceeding national averages.

Read why leading companies across industries chose Carrot’s inclusive fertility healthcare and family-forming support for their employees.

A Dynamic Duo: Founding team brings technology and clinical expertise.

Achieving “product-market fit” – or alignment of a product’s value proposition to an underserved market need – is critical to any startup’s success. Carrot Fertility’s two female co-founders, Tammy Sun and Dr. Asima Ahmad, MD, MPH, bring different yet essential competencies to the challenge of building a better fertility offering.

Prior to the founding of Carrot, Sun was head of partnerships at Evernote and personally experienced the limits of existing fertility offerings. In an MSNBC feature, she shared that at a doctor’s appointment, she found out she had “premature ovarian failure,” which meant that her ovaries were essentially getting older significantly faster than her biological age would imply — and that she would go through early onset menopause. Her co-founder, Dr. Ahmad, brought to Carrot her expertise as a clinical leader in infertility with a thriving medical practice as a reproductive endocrinology and infertility specialist at Fertility Centers of Illinois.

“When we met Tammy and Asima, we found a talented team with a compelling vision and business model for addressing a key gap in the industry faced by many patients and employers.”

-Carl Byers, Partner, F-Prime Capital

Future of Digital Health: F-Prime’s commitment to driving innovation.

Carrot’s mission to provide fertility care for all and its dedicated co-founders made F-Prime’s decision to invest in the company a straightforward one. In August 2020, we were delighted to invest in Carrot Fertility’s $24 million Series B funding alongside U.S. Venture Partners and existing investors including CRV, Precursor Ventures, Maven Ventures, and Uncork Capital. Later, we welcomed Orbimed and Tiger Global to the ongoing effort to enable success for Carrot and all of its stakeholders.

Like Carrot, our team and portfolio companies aim to reshape the healthcare system to address pressing challenges and enable everyone to access the care they need.

Subscribe to our newsletter to get the latest updates on how our portfolio companies continue to lead the way in their respective fields.

Carolyn Haley, MS, CPA

Carolyn Haley joined F-Prime in 2023 where she serves as a Partner, Chief Operating Officer, and Chief Financial Officer and manages the administrative functions of the firm.

Prior to joining F-Prime, Carolyn was a partner and Global Head of Operations and Finance at GMO LLC where she was responsible for the firm’s strategic operating model and led various functions including Operations, Finance, Tax, Corporate Accounting, Enterprise Data Management and Investment Analysis. She also served as President and Trustee of the GMO Trust group of mutual funds, was a member of the Board of Directors for all of the firm’s subsidiaries and a served on several of the firm’s key governance committees, including the ESG and the Diversity, Equity and Inclusion Groups. Prior to GMO, Carolyn was Treasurer and Chief Compliance Officer at Tekla Capital Management (formerly Hambrecht & Quist Capital Management LLC). Prior to that, she was a senior manager with PricewaterhouseCoopers LLP where she served a broad range of clients in the asset management industry.

Ms. Haley earned her bachelor’s degree in Economics and History from Boston University, graduating magna cum laude, and her Masters of Science in Accounting from the Isenberg School of Management at the University of Massachusetts, Amherst. She is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants.

Paradigm Health

Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.

Zeen Health

Zeen Health is a health IT company developing prescription digital therapeutics (PDT) for various mental health disorders.

FCB Health

FCB Health is a health insurance and services company that aims to resolve the longstanding financial burden of rising medical expenses in rural China. FCB Health was acquired by Interpublic Group (IPG).

NeuroSmart

NeuroSmart is an operator of an education and research center focusing on autism. The company helps patients with autism through scientific research and early intervention application, providing families with a comprehensive scientific family intervention program.

Rippl

Rippl is a new kind of mental health company focused on seniors and obsessed with its clinicians. Seniors with mental health challenges, especially neurocognitive conditions like Alzheimer’s disease and other dementias, are overlooked and under cared for, often without access to high quality, real-time, practical care. Leveraging a value-based approach, disruptive technology, and a relentless focus on empowering and enabling its clinicians, Rippl is pioneering a new care model to dramatically expand access to high quality, wraparound mental health care for seniors, their families, and caregivers. Rippl provides 24/7 support and personalized care when and where they need it – on the phone, online or in their living rooms.

Elucidata

Elucidata was founded in 2015 by University of Chicago and MIT graduate Dr. Abhishek Jha and IIT Delhi alumnus Swetabh Pathak. The company’s cutting-edge platform Polly operates on unique Bio-NLP technology that cleans, and links 26+ R&D data types and caters to companies in various stages of their drug discovery process. The platform helps data science teams scale by providing them 70 TB of ML-Ready biomedical data, from ~30 public and proprietary sources. Today, 3 of the top 10 pharmaceutical companies are using Polly to fast track their R&D initiatives.

WellBeam

WellBeam transforms workflows between MD teams and their post-acute partners continuing the medical care of their patients. Through its EMR integrated solution, WellBeam reduces home health readmissions, drives provider wellness through less administrative workflow, and captures underbilled CMS codes available to providers.